• MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.

Some psoriasis studies you shouldn't miss

September 12, 2018
Dermatology Times Staff

In this slideshow, we highlight some of this year's clinical advances in psoriasis and plaque psoriasis.

In this slideshow, we highlight some of this year's clinical advances in psoriasis and plaque psoriasis.

SKIN CANCER CHECKS IN PSORIASIS:  As dermatologists become increasingly aware of comorbidities associated with psoriasis, questions of associated malignancy risk remain. Dr. Megan Noe emphasizes the need for skin cancer checks. (©SweetheartStudio/Shutterstock.com)

 

(©SweetheartStudio/Shutterstock.com)

ARTHRITIS IN PSORIASIS IS NOT AS COMMON AS WE ONCE THOUGHT:  The prevalence of psoriatic arthritis in patients with psoriasis worldwide appears to be around 20 percent, shows a meta-analysis published in JAAD. (©TernavskaiaOlgaAlibec/Shutterstock.com)

MEDITERRANEAN DIET MAY REDUCE PSORIASIS SEVERITY:  A JAMA Dermatology study shows that adherence to a Mediterranean diet high in anti-inflammatory nutrients may lessen psoriasis severity. (©ItsAlDente/Shutterstock.com)

HIGHER SURVIVAL RATES IN PLAQUE PSORIASIS:  Ustekinumab has a higher drug survival rate than adalimumab, etanercept and infliximab, confirms a study of plaque psoriasis patients published in the Journal of Cutaneous Medicine and Surgery. (©MOMOTaRO/Shutterstock.com)

IL-23 GUSELKUMAB SIGNIFICANTLY IMPROVES SYMPTOMS IN PSORIATIC ARTHRITIS:  This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.  (©AdamJ/Shutterstock.com)

INDIVIDUALIZED BIOLOGIC THERAPY:  A new study advises selecting biologic therapies for psoriasis based on individual factors such as patients' comorbidities, preferences and clinical situation, as well as the advantages and disadvantages of particular biologic treatments. (©SweetheartStudio/Shutterstock.com)

ADALIMUMAB TARGETS PS0 INFLAMMATION, NOT NECESSARILY HEART DISEASE:  Adalimumab may be effective for plaque psoriasis, but not heart disease and other inflammatory conditions associated with the condition. This study confirms that the inflammatory process is unique and that one treatment may not apply to other inflammatory conditions. (©SweetheartStudio/Shutterstock.com)

TEST MAY REDUCE THE NEED FOR LIVER BIOPSIES IN PSORIASIS:  A JAMA Dermatology study raises the possibility of adopting the NASH FibroSure test to detect hepatic fibrosis in psoriasis patients and minimize the number of liver biopsies. (©SweetheartStudio/Shutterstock.com)

GUSELKUMAB MAY PROVE TO BE THE TREATMENT OPTION FOR DIFFICULT-TO-TREAT PSORIASIS:  For psoriasis in difficult locations including the scalp, palms and soles, guselkumab outperformed adalimumab and placebo, shows a study published online in JAMA Dermatology.  (©LipowskiMilan/Shutterstock.com) 

PreviousNext